CapForce, Inc. (CFOR)
6.02
-0.88
(-12.75%)
USD |
OTCM |
Nov 05, 16:00
CapForce Net Income (Quarterly) : 42.47M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 42.47M |
| March 31, 2026 | -0.7106M |
| December 31, 2025 | 21.13M |
| September 30, 2025 | -0.6087M |
| June 30, 2025 | 3.51M |
| March 31, 2025 | -0.4081M |
| December 31, 2024 | 4.350M |
| September 30, 2024 | 8.931M |
| June 30, 2024 | -1.576M |
| March 31, 2024 | 0.288M |
| December 31, 2023 | -17.04M |
| September 30, 2023 | -4.063M |
| June 30, 2023 | -5.827M |
| March 31, 2023 | -5.737M |
| December 31, 2022 | -10.53M |
| September 30, 2022 | -14.10M |
| June 30, 2022 | -5.840M |
| March 31, 2022 | -6.804M |
| December 31, 2021 | -6.906M |
| September 30, 2021 | -6.057M |
| June 30, 2021 | -7.087M |
| March 31, 2021 | -14.85M |
| December 31, 2020 | -7.110M |
| September 30, 2020 | -7.676M |
| Date | Value |
|---|---|
| June 30, 2020 | -7.476M |
| March 31, 2020 | -3.949M |
| December 31, 2019 | -2.518M |
| September 30, 2019 | -3.482M |
| June 30, 2019 | -2.593M |
| March 31, 2019 | -3.853M |
| December 31, 2018 | -3.732M |
| September 30, 2018 | -3.255M |
| June 30, 2018 | -3.332M |
| March 31, 2018 | -3.048M |
| December 31, 2017 | -2.938M |
| September 30, 2017 | -3.269M |
| June 30, 2017 | -4.208M |
| March 31, 2017 | -4.978M |
| December 31, 2016 | -4.76M |
| September 30, 2016 | -4.848M |
| June 30, 2016 | -5.053M |
| March 31, 2016 | -4.506M |
| December 31, 2015 | -4.728M |
| September 30, 2015 | -4.671M |
| June 30, 2015 | -5.359M |
| March 31, 2015 | -2.595M |
| December 31, 2013 | -2.912M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Phio Pharmaceuticals Corp. | -4.138M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 3.864B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 37.92M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 50.00M |
| Total Expenses (Quarterly) | 7.529M |
| EPS Diluted (Quarterly) | 3.384 |
| Enterprise Value | 76.45M |
| Gross Profit Margin (Quarterly) | 89.90% |
| Profit Margin (Quarterly) | 84.94% |
| Earnings Yield | 88.56% |
| Operating Earnings Yield | 96.42% |
| Normalized Earnings Yield | 88.56 |